Pipeline by indication
NETRIS Pharma is conducting a large Clinical Development Plan with its lead asset NP137. A pipeline of new products targeting other ligands is also in construction.
Study
| Program Target | Indication | Discovery | IND Enabling | Phase I | Phase II | Late-Stage Development |
|---|---|---|---|---|---|---|
|
ImmunoNET NCT05605496
NP137 + Approved Immune Checkpoint
|
• NSLCC (*) |
|||||
|
NeckNET
NP137 + Approved Immune Checkpoint
|
HNSCC (*) |
|||||
|
PANCNET1
NP137 + Folfirinox
|
Metastatic Pancreatic Cancer |
|||||
|
GLIONET1
NP137 + Stupp Protocol
|
Glioblastoma |
|||||
|
EndoNET
|
Endometriosis |
|||||
|
NP137-Indium
|
Netrin-1 expressing cancer |
|||||
|
FibroNET
|
Fibrosis |
(*) Indications :
- NSCLC : Non-Small Cell Lung Cancer
- HNSCC : Head and Neck Squamous Cell Carcinoma
- PDAC : Pancreatic Ductal Adenocarcinoma
- HCC : Hepatocellular Carcinoma
The dotted lines represent the extent to which each program is expected to advance.
Clinical Development
NETRIS Pharma focuses NP137 development on tumor types where the Epithelial to Mesenchymal Transition (EMT) is a central mechanism of diffusion and resistance to treatment. Several clinical trials are well underway to demonstrate the ability of NP137 to overcome resistance, delay tumor progression and extend overall survival for patients. Through its long-term collaboration with the Leon Bérard Comprehensive Cancer Center, NETRIS Pharma accesses a unique set of multidisciplinary technological platforms to conduct ambitious ancillary research programs to identify relevant biomarkers and better characterize patients who shall most likely benefit from the treatment.
